Tuberculosis (TB) Diagnostics Market to Grow at a CAGR of 6.3% During Forecast Period; Need for Accurate and Efficient Diagnostic Solutions to Fuel Market Growth

The global tuberculosis (TB) diagnostics market size was valued at USD 2.40 billion in 2025. The market is projected to grow from USD 2.53 billion in 2025 to USD 4.14 billion by 2034, exhibiting a CAGR of 6.3% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Tuberculosis (TB) Diagnostics Market Size, Share & Industry Analysis, By Type (Culture-based Diagnostics, Sputum Smear Microscopy, Rapid Molecular Diagnostics, and Others), By Disease Site (Pulmonary Tuberculosis and Extrapulmonary Tuberculosis), By End-user (Diagnostic & Reference Laboratories, Hospitals, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034”.

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but also capable of impacting other organs such as the brain and spine. It is typically diagnosed through skin and blood tests. With its rising prevalence, the need for accurate and efficient diagnostic solutions to curb its transmission is growing, which is expected to drive strong demand for tuberculosis diagnostics.

Launch of AmPORE-TB by Oxford Nanopore and bioMerieux to Enable Rapid Detection of Drug-Resistant TB

In November 2025, Oxford Nanopore and bioMerieux launched AmPORE-TB, a Research-Use-Only solution on the GridION platform that detects drug-resistance mutations across 24 genes in the M. tuberculosis complex with same-day results, recognized by WHO as a recommended targeted NGS method for TB AMR detection.

Rising Incidence of TB in Emerging Countries to Propel Market Growth

The rising incidence of TB in emerging and high-burden countries is a key driver for tuberculosis (TB) diagnostics market growth, increasing demand for accurate and advanced diagnostics. This trend is encouraging companies to invest in faster, more precise technologies such as NAATs and rapid molecular assays. With proven effectiveness, these solutions are being increasingly adopted by healthcare systems, while health agencies continue to update diagnostic guidelines to include them.

However, expensive advanced tuberculosis (TB) diagnostics solutions may hamper market growth.

Strategic Introductions of Novel Products by Major Players to Boost Market Growth

In 2025, BIOMÉRIEUX, F. Hoffmann-La Roche Ltd., and Abbott emerged as leading players, capturing a substantial share of the market. Their leadership is attributed to a robust product portfolio and consistent introduction of novel products. Other key players, such as Thermo Fisher Scientific Inc. and QIAGEN, are intensifying their focus on R&D to develop innovative diagnostic solutions and expand their global footprint.

Notable Industry Development

• November 2025: Co-Diagnostics outlined its molecular TB test development and implementation strategy at The Union World Conference on Lung Health. The company noted that clinical performance testing was expected to begin soon, with plans for potential introduction in the Indian and South African markets, highlighting that making decentralized PCR accessible across India’s nearly 30,000 primary health centers would be a critical transition for TB testing in the country.

List of Key Companies Profiled in the Report

• Hoffmann-La Roche Ltd (Switzerland)
• BIOMÉRIEUX (France)
• QIAGEN (Netherlands)
• BD (U.S.)
• Cepheid (Danaher) (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• Hologic, Inc. (U.S.)
• Hain Lifescience GmbH (Germany)
• Revvity (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/tuberculosis-tb-diagnostics-market-102009

Further Report Findings

• North America dominates the tuberculosis (TB) diagnostics market share. The region’s position is driven by the rising prevalence of TB, leading to an increase in diagnostic testing. Additionally, the presence of major market players in the region is anticipated to support market growth over the forecast period.
• Asia Pacific’s market is expected to be the second-largest. The region’s growth is attributed to improving healthcare infrastructure across Asian countries, a high TB disease burden, and growing demand for better treatment outcomes.
• On the basis of type, in 2025, the rapid molecular diagnostics segment led the market and is expected to maintain a substantial share throughout the forecast period. Its growth is driven by the high efficiency and accuracy it offers in TB diagnosis. Additionally, upcoming new products launched in this segment are likely to accelerate its growth further.

Table of Segmentation